Myriad Genetics, Inc. (NASDAQ:MYGN) mean price target has been set at $23.900 by Thomson Reuters. The group worked out on the stock recommendations given by analysts in the First Call poll. Further, it is possible that the company may register per share earnings of $0.310 in the near-term quarter and $1.780 for the ongoing fiscal. The market cap of Myriad Genetics, Inc. was recorded at $1.42B after the stock closed at $19.700 in last trading day.
What The Valuation Says?
The price/earnings ratio is taken in the list of ratios that leads to a stock’s valuation. Commonly named as P/E ratio, it helps investors know where the company stands in the market. It is derived by dividing share’s latest price by per-share earnings. Myriad Genetics, Inc. (NASDAQ:MYGN) has a P/E ratio of 13.652. Investors can identify how the stock is doing in the market by estimating Price-to-Earnings Growth ratio.
Myriad Genetics, Inc. (NASDAQ:MYGN) PEG ratio sits at 1.750. A low PEG ratio offers an investment opportunity to the opportunistic traders and investors. In case a stock has a reading in between 0 and 1, it represents undervalued stock. A reading of 1 and 2 represents fairly priced stocks.
The technical analysis of Myriad Genetics, Inc. visibly illustrates that the 50-day MA of Myriad Genetics, Inc. is $30.805, and stock is trading $-10.600 points away or -34.410% from its 50-day moving average of $30.805. Further it is trading $-14.385 or -41.586% away its 200-day moving average of $34.590. Myriad Genetics, Inc. (NASDAQ:MYGN) 52-week high is $46.240 and the 52-week low is $19.100. This represents that if the stock moves $-26.035 points up on the chart to it will make a 52-week high. But, if it declines +5.785%, then the shares price can hit a new 52-week low.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...